OncoSec Medical Inc (ONCS)-製薬・医療分野:企業M&A・提携分析

【英語タイトル】OncoSec Medical Inc (ONCS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA8014209)・商品コード:DATA8014209
・発行会社(調査会社):GlobalData
・発行日:2017年11月22日
・ページ数:64
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. It is also identifying and developing novel immune-targeting agents for use with the ImmunoPulse platform. The company conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US.

OncoSec Medical Inc (ONCS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
OncoSec Medical Inc, Medical Devices Deals, 2011 to YTD 2017 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
OncoSec Medical Enters into Agreement with Jounce Therapeutics 12
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 13
OncoSec Medical Enters into Research Agreement with University of Washington 14
Licensing Agreements 15
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 15
Inovio Pharma Enters Into Licensing Agreement With OncoSec Medical 16
Equity Offering 17
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 17
OncoSec Medical Raises USD7 Million in Private Placement of Shares 18
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 20
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 21
OncoSec Medical Raises USD10 Million in Registered Direct Offering 22
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 23
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 24
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 25
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 26
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 27
OncoSec Medical Completes Public Offering Of Units For US$8 Million 28
OncoSec Medical Inc – Key Competitors 29
OncoSec Medical Inc – Key Employees 30
OncoSec Medical Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Oct 25, 2017: OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017 32
Jun 01, 2017: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017 34
Mar 16, 2017: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017 36
Dec 08, 2016: OncoSec Announces First Quarter Financial Results for Fiscal Year 2017 37
Oct 13, 2016: OncoSec Announces Fourth Quarter and Year End Results for Fiscal Year 2016 38
Jun 09, 2016: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016 39
Mar 08, 2016: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2016 and Calendar 2016 Milestones 40
Corporate Communications 41
Nov 07, 2017: OncoSec Appoints Daniel J. O’Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company 41
Sep 07, 2017: OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors 42
Sep 06, 2016: OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer 43
Apr 15, 2016: OncoSec Announces New Senior Leadership Responsibilities 44
Feb 29, 2016: OncoSec Appoints Sharron Gargosky, PhD, as Head of Clinical Development and Operations 45
Product News 46
10/18/2016: OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development 46
04/19/2016: OncoSec Presents Positive Melanoma Clinical Data at American Association for Cancer Research Annual Meeting 2016 47
04/13/2016: OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data 48
Product Approvals 49
Jun 08, 2017: OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma 49
Feb 27, 2017: OncoSec Granted FDA Fast Track Designation for ImmunoPulse IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab 50
Clinical Trials 51
Apr 03, 2017: OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting 51
Mar 21, 2017: OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models 52
Feb 23, 2017: OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients 53
Feb 08, 2017: OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February 54
Nov 17, 2016: OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016 55
Nov 11, 2016: OncoSec Presents Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 56
Nov 08, 2016: OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 57
Nov 01, 2016: OncoSec to Present at Scientific and Investment Conferences and to Host Inaugural Investor and Analyst Day in November 58
Oct 13, 2016: OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016 59
Aug 15, 2016: OncoSec Announces Peer-Reviewed Publication of T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Therapy in Melanoma 60
Jun 16, 2016: OncoSec Presents Preliminary Findings from Head and Neck Phase II Clinical Trial at EUROGIN 2016 Conference 61
Jun 06, 2016: OncoSec Collaborators Present Results of Novel T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Monotherapy 62
Mar 02, 2016: OncoSec Completes Patient Enrollment in Phase II Extension Study of ImmunoPulse IL-12 in Melanoma 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
OncoSec Medical Inc, Deals By Therapy Area, 2011 to YTD 2017 9
OncoSec Medical Inc, Medical Devices Deals, 2011 to YTD 2017 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
OncoSec Medical Enters into Agreement with Jounce Therapeutics 12
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 13
OncoSec Medical Enters into Research Agreement with University of Washington 14
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 15
Inovio Pharma Enters Into Licensing Agreement With OncoSec Medical 16
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 17
OncoSec Medical Raises USD7 Million in Private Placement of Shares 18
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 20
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 21
OncoSec Medical Raises USD10 Million in Registered Direct Offering 22
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 23
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 24
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 25
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 26
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 27
OncoSec Medical Completes Public Offering Of Units For US$8 Million 28
OncoSec Medical Inc, Key Competitors 29
OncoSec Medical Inc, Key Employees 30

★調査レポート[OncoSec Medical Inc (ONCS)-製薬・医療分野:企業M&A・提携分析] (コード:DATA8014209)販売に関する免責事項を必ずご確認ください。
★調査レポート[OncoSec Medical Inc (ONCS)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆